Transcriptomics Technologies Market, By Replacement Therapy (Estrogen, Human Growth Hormone, Testosterone and Thyroid), By Route of Administration, By Disease, and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated

Report ID: AMI-77905812 | Publihed: 01-Jul-2020 | No of Pages: 216


USD 3995
USD 5795


Publish Date:


Total pages:


The Transcriptomics Technologies market is estimated to represent a global market of USD 2.69 billion by 2019 with growth rate of 5.5%.

Market Dynamics

Transcriptomics is defined as the study of RNA transcripts that are produced by the genome under specific conditions in specified cell bodies. These transcriptomics datasets are products by various high-throughput methods such as next-generation sequencing and microarray analysis as it usually demands quantitative measurement of thousands of genes. Primary aim behind transcriptome analysis is to identify differentially expressed genes and to gain proper understanding on disease condition.

According to the International Review of Cell and Molecular Biology transcriptomic is aimed to establish the genetic cause of disease conditions by analyzing DNA or RNA profiles through advanced computational models. The industry is majorly driven by the continuous technological up-gradation, rising demand for more compact and reliable products, and the introduction of robust and efficient methodologies. For instance, Affymetrix, Inc. introduced the GeneChip microarray in 1993 and to date, the company is engaged in continuous product modification to achieve higher efficiencies.

Genome Analyzer by Illumina, Inc., AB SOLiD by Life Technologies Corporation, and Roche 454 and HeliScope by Helicos Biotechnologies are the technologically updated system available in the market currently. Furthermore, growing demand for personalized medicine ensures a potential opportunity in the commercialization of transcriptome research results. Despite the industry is on a high growth trajectory, some potential threats exist such as lack of skilled personnel and efficient data tools that will likely to restraint the growth prospects going forward.

COVID-19 Impact & Recovery Analysis

The proposed report, Transcriptomics Technologies market from AnalystView Market Insights suggests three possible forecast scenarios (probable, optimistic, and pessimistic) considering the COVID-19 impact. Our ongoing research analysis amplifies our framework to ensure the inclusion of underlying COVID-19 crisis impact and potential paths forward. The designed report is delivering detailed insights on COVID-19 considering the changes in consumer demand, purchasing patterns, re-routing of the supply chain, and the significant interventions of governments. The updated study provides insights, and forecast, considering the COVID-19 impact on the market.

Regional Takeaway

Regionally, North America, specifically the U.S., accounted for the largest share of the global market. The U.S. is accounted for the one-third of the global biotechnology market. As per the Biotechnology Innovation Organization, more than 2,000 public and private biotechnology companies based in the U.S., where commercial biotechnology research and development activities are growing at steady growth rate. Such facts would, in turn, establish the strong platform for the growth of transcriptomics industry in the country, augmenting the market growth. On another side, the industry in Asia Pacific region is expected to soar as increasing number of key players are preparing to inject new investment.

Key Vendor Takeaway

The industry is consolidated in nature, where a limited number of players control significant revenue share. Key players such as Life Technologies Corporation, Illumina, Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., and Affymetrix, Inc. emerged as the prominent players in this market. Of these, Agilent holds highest share (over 20%) of the global transcriptomics market.

Still, in such a consolidated landscape, a large number of small-scale or large-scale players are competing to capture large customer base. In February 2015, Beckman Coulter Inc. launched the service of processing degraded RNA samples of the mouse, human, rat, and plants. This is likely to enhance the clarity on providing a more complete transcriptome analysis.

The market size and forecast for each segment has been provided for the period 2016 to 2027, considering 2019 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2021 to 2027 for every reported segment.

The years considered for the study are:

Historical Year – 2016 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2027

The proposed reports analyse and evaluates the COVID-19 impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.


The scope of this report covers the market by its major segments, which include as follows:


Polymerase Chain Reaction (PCR)
Gene Regulation Technologies
Next Generation Sequencing

North America
Rest of Europe
Asia Pacific
Rest of APAC
Rest of the World
Middle East and Africa
Latin America

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.